



FILE COPY

9/14

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: S. W. Fesik, et al.

Serial No.: 09/716,395

Filed: November 20, 2000

For: MUTANT BCL-2 PROTEINS AND
USES THEREOF

Attorney Docket No.: 6752.US.O1

Date: March 28, 2002

Examiner: B. Brumback

Group Art Unit: 1642

Certificate of Facsimile Transmission under 37 CFR
§1.8(a):

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via facsimile, said transmission to be completed before midnight Eastern time on the date shown below, addressed to the following recipient:

Assistant Commissioner for Patents
Attn: Examiner Brenda G. Brumback
Group Art Unit 1642
Washington, D.C. 20231

Recipient Telefax Number: (703)-872-9306
Kimberly A. Ionib 03/28/02
Kimberly A. Ionib Date

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

DEC 27 2002

TECH CENTER 1600/2900

Dear Sir:

Please amend the above-identified application as indicated below.

IN THE CLAIMS

Please CANCEL claims 15-18, WITHOUT PREJUDICE.

Remarks


This communication is in response to the Office Action, mailed March 11, 2002 in the above identified patent application. Claims 1-18 currently are pending. In the Office Action, the Examiner restricted Applicants' invention to one of two designated groups, namely, Group I (claims 1-14, drawn to a mutant human Bcl-2 protein) and Group II (claims 15-18, drawn to a method for identifying substances which bind to a Bcl-2 protein). Applicants hereby elect the invention of Group I, without traverse. Applicants reserve the right to file a divisional application directed to the non-elected subject matter.



23492

ABBOTT LABORATORIES
Telephone: (847) 938-3137
Facsimile: (847) 938-2623

Respectfully submitted,
S. W. Fesik, et al.


Dianne Casuto
Registration No. 40,943
Attorney for Applicants